Search Within

Jamie Erin Chaft

Formats
  1. Meeting Abstract (146)
  2. Journal Article (127)
  3. Review (9)
  4. Editorial (2)
  5. Miscellaneous (2)
  6. Conference Paper (1)
  7. Guidelines (1)
  8. Research Letter (1)
Groups
  1. Department of Medicine (289)
  2. Solid Tumor Oncology Division (289)
  3. Thoracic Oncology (289)
  4. Surgery (112)
  5. Department of Pathology and Laboratory Medicine (96)
  6. GSK Faculty (76)

More Groups

People
  1. Mark Kris (107)
  2. Matthew Hellmann (68)
  3. Andreas Rimner (59)
  4. David Jones (49)
  5. Abraham Wu (47)
  6. Valerie Rusch (47)

More People

Years
  1. 2025 (5)
  2. 2024 (29)
  3. 2023 (28)
  4. 2022 (23)
  5. 2021 (23)
  6. 2020 (20)

More Years

Publications
  1. Journal of Thoracic Oncology (60)
  2. Journal of Clinical Oncology (57)
  3. International Journal of Radiation Oncology, Biology, Physics (25)
  4. Annals of Oncology (13)
  5. Journal of Thoracic and Cardiovascular Surgery (10)
  6. Clinical Cancer Research (9)

More Publications

Publishers
  1. Elsevier Inc. (102)
  2. American Society of Clinical Oncology (61)
  3. American Association for Cancer Research (23)
  4. Oxford University Press (16)
  5. Nature Publishing Group (11)
  6. Mosby Elsevier (10)

More Publishers

Results (289)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Exploratory analysis of ctDNA and imaging response in the phase I/II CHORUS study of canakinumab with chemoradiation and durvalumab consolidation for stage Ill NSCLC
    Meeting Abstract

    Shaverdian, N.; Offin, M.; Charalambous, K.; Gelblum, D.; Santini, F.; Boe, L. A.; Shepherd, A. F.; Gewanter, R. M.; Shin, J. Y.; Rimner, A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • The impact of the time of day of radiotherapy and systemic therapy on disease control in locally advanced non -small cell lung cancer treated with chemoradiation and durvalumab
    Meeting Abstract

    McMillan, M. T.; Shepherd, A. F.; Cooper, A. J.; Schoenfeld, A. J.; Wu, A. J.; Simone, C. B. 2nd; Iyengar, P.; Gelblum, D.; Chaft, J.; Gomez, D. R.; more...
    International Journal of Radiation Oncology, Biology, Physics (2024)

    Fulltext@MSK | Save
  • Clinicopathologic and genomic features associated with brain metastasis after resection of lung adenocarcinoma
    Journal Article

    Dunne, E. G.; Fick, C. N.; Mastrogiacomo, B.; Tan, K. S.; Toumbacaris, N.; Vanstraelen, S.; Rocco, G.; Chaft, J. E.; Iyengar, P.; Gomez, D.; more...
    JTCVS Open (2024)

    Fulltext@MSK | Save
  • Characteristics and outcomes of patients with SMARCA4-deficient undifferentiated thoracic tumors
    Meeting Abstract

    Cooper, A.; Ricciuti, B.; Gagne, A.; Sholl, L.; Di Federico, A.; Awad, M.; Aldea, M.; Ghigna, M. R.; Grecea, M.; Chaft, J.; more...
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): A randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Spicer, J. D.; Garassino, M. C.; Wakelee, H.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; Chen, K. N.; Dooms, C.; Majem, M.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • A promising step forward with giant leaps ahead
    Editorial

    Shaverdian, N.; Li, B. T.; Isbell, J.; Chaft, J. E.
    Journal of Thoracic Oncology (2024)

    Fulltext@MSK | Save
  • Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Garassino, M. C.; Wakelee, H. A.; Spicer, J.; Liberman, M.; Kato, T.; Tsuboi, M.; Lee, S. H.; Chen, K. N.; Dooms, C. A.; Majem, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Outcomes with perioperative durvalumab (D) in pts with resectable NSCLC and baseline N2 lymph node involvement (N2 R-NSCLC): An exploratory subgroup analysis of AEGEAN
    Meeting Abstract

    Heymach, J.; Reck, M.; Mitsudomi, T.; Taube, J. M.; Spira, A. I.; Chaft, J. E.; Doherty, G. J.; Mann, H.; Fouad, T. M.; Harpole, D. H.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry
    Meeting Abstract

    Luo, J.; Kim, J. J.; Walton, S. A.; Nguyen, T.; Paik, P. K.; Chaft, J. E.; Hsu, R.; Piha-Paul, S. A.; Janne, P. A.; Sholl, L. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC)
    Meeting Abstract

    Lee, J. M.; Spicer, J.; Nair, S.; Khattak, A.; Brown, M.; Meehan, R. S.; Shariati, N. M.; Deng, X.; Samkari, A.; Chaft, J. E.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save